GEN

Organ-Chip ALS Model Uses Patient iPSCs to Uncover Early Disease Progression

Amyotrophic lateral sclerosis (ALS) remains one of the most devastating and biologically elusive neurodegenerative diseases. Despite decades of research, its underlying mechanisms are still not fully understood. The condition presents a complex and highly ...
Hosted on MSN

New drug may slow progression of ALS in small group of patients, study finds

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very specific mutation -- SOD1 -- which applies to only 2% of the ...
ALS News Today

Scientists find promising 3 drug combo for sporadic ALS using new models

A triple combination therapy identified using newly developed cell models is showing promise for treating sporadic ALS, per a study.
Yahoo

New Study Links Immune System To ALS Progression, Offering Hope For Treatments

Add Yahoo as a preferred source to see more of our stories on Google. Wheelchair, isolated view Image by Kub The Shadow Simple ManShutterstock A newly published study says that the body’s own immune system may be responsible for driving the progression ...
Business Wire

Mounting Evidence Demonstrates Neuvivo’s NP001 Spares Lung Function and Substantially Extends Survival in ALS Patients

Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 significantly decreased inflammatory biomarkers ...
STAT

Autoimmune responses found in ALS, pointing to a new way to view the deadly disease

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have autoimmune responses, a finding with the potential to ...

I AM ALS's Push for Progress Campaign Reaches Major Milestone, Securing Unprecedented Federal Research Investment and Bringing Total Secured Since Founding To $1.6 Billion

I AM ALS announced a major milestone in its Push for Progress campaign: thanks to our community of advocates and partners, we've secured $313 million in funding for ALS research in the 2026 federal budget to accelerate research,
Yahoo

Air pollution linked to an increased risk of developing ALS, study finds

Add Yahoo as a preferred source to see more of our stories on Google. Long-term air pollution exposure may raise ALS risk and speed disease progression, according to a large Swedish study. (CREDIT: AI-generated image / The Brighter Side of News) A recent ...
Morningstar

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral sclerosis (ALS).